CORV - Correvio Pharma Corp.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Currency in USD

Valuation Measures

Market Cap (intraday) 587.04M
Enterprise Value 3121.63M
Trailing P/E N/A
Forward P/E 1-4.00
PEG Ratio (5 yr expected) 1-0.08
Price/Sales (ttm)2.85
Price/Book (mrq)N/A
Enterprise Value/Revenue 33.98
Enterprise Value/EBITDA 6-6.35

Trading Information

Stock Price History

Beta (3Y Monthly) 1.11
52-Week Change 3-65.57%
S&P500 52-Week Change 3-0.33%
52 Week High 35.1600
52 Week Low 31.4300
50-Day Moving Average 31.8829
200-Day Moving Average 32.6665

Share Statistics

Avg Vol (3 month) 3125.24k
Avg Vol (10 day) 3174.49k
Shares Outstanding 5N/A
Float 45.95M
% Held by Insiders 12.98%
% Held by Institutions 147.92%
Shares Short (Jul 31, 2019) 4506.38k
Short Ratio (Jul 31, 2019) 44.45
Short % of Float (Jul 31, 2019) 4N/A
Short % of Shares Outstanding (Jul 31, 2019) 41.27%
Shares Short (prior month Jun 28, 2019) 41.18M

Dividends & Splits

Forward Annual Dividend Rate 4N/A
Forward Annual Dividend Yield 4N/A
Trailing Annual Dividend Rate 3N/A
Trailing Annual Dividend Yield 3N/A
5 Year Average Dividend Yield 4N/A
Payout Ratio 40.00%
Dividend Date 3N/A
Ex-Dividend Date 4N/A
Last Split Factor (new per old) 25/1
Last Split Date 3Apr 12, 2013

Financial Highlights

Fiscal Year

Fiscal Year Ends Dec 31, 2018
Most Recent Quarter (mrq)Jun 30, 2019


Profit Margin -107.91%
Operating Margin (ttm)-75.42%

Management Effectiveness

Return on Assets (ttm)-23.02%
Return on Equity (ttm)-453.99%

Income Statement

Revenue (ttm)30.59M
Revenue Per Share (ttm)0.81
Quarterly Revenue Growth (yoy)19.60%
Gross Profit (ttm)20.38M
EBITDA -19.14M
Net Income Avi to Common (ttm)-33.01M
Diluted EPS (ttm)-0.8790
Quarterly Earnings Growth (yoy)N/A

Balance Sheet

Total Cash (mrq)12.88M
Total Cash Per Share (mrq)0.25
Total Debt (mrq)45.63M
Total Debt/Equity (mrq)N/A
Current Ratio (mrq)1.68
Book Value Per Share (mrq)-0.00

Cash Flow Statement

Operating Cash Flow (ttm)-25.6M
Levered Free Cash Flow (ttm)-11.31M